Cardiff Oncology
Cardiff Oncology is a clinical-stage biotechnology company focused on developing novel cancer therapies by inhibiting PLK1, with a leading asset, onvansertib, targeting various metastatic cancers.
Company Overview
Cardiff Oncology is a clinical-stage biotechnology company specializing in the development of novel cancer therapies. The company utilizes PLK1 inhibition as a core strategy to innovate treatments across a variety of cancer types. Located at 11055 Flintkote Ave, San Diego, CA 92121, Cardiff Oncology is dedicated to addressing unmet medical needs in oncology.
Lead Asset: Onvansertib
The lead asset of Cardiff Oncology is onvansertib, a PLK1 inhibitor currently being evaluated in combination with standard care therapeutics. Onvansertib's design aims to offer new treatment options in cancer therapy, particularly targeting areas where there is a significant demand for innovative solutions.
Clinical Programs
Cardiff Oncology is actively conducting several clinical programs involving onvansertib. These programs focus on 1st Line RAS-Mutated Metastatic Colorectal Cancer (mCRC), 2nd Line KRAS-Mutated Metastatic Colorectal Cancer (mCRC), and Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC). Each program targets specific patient populations with significant need for effective treatment options.
Location and Contact Information
Cardiff Oncology is headquartered at 11055 Flintkote Ave, San Diego, CA 92121. For inquiries, the company can be reached at 858-952-7570. This location serves as the operational hub for their research and development activities focused on cancer therapy innovations.